All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

FREEDOM trial: How can we manage AEs associated with fedratinib?

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Ruben A. Mesa, UT Health San Antonio, San Antonio, US. We asked, FREEDOM trial: How can we manage adverse events (AEs) associated with fedratinib?

FREEDOM trial: How can we manage AEs associated with fedratinib?

In this video, Mesa discusses results from the FREEDOM trial (NCT03755518), a phase 3b, multicenter study evaluating the safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib. Lastly, he mentions the management of fedratinib side effects, including gastrointestinal complications, and monitoring of thiamine levels.

 

Share: